Skip to main content

Table 1 Demographic characterization, CSF results, and NfL concentrations in the diagnostic groups

From: Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

 

Controls

MCI-AD

ADD

N (male + female)

41 (22 + 19)

25 (10 + 15)

33 (13 + 20)

Age (years)

52.5 ± 13.1

71.3 ± 8.4

70.8 ± 7.6

MMSE

29.3 ± 0.9a

26.7 ± 2.1b

21.2 ± 3.4

CSF Aβ1–42 (pg/mL)

1025 ± 308

585 ± 116

536 ± 114

CSF Aβ1–40 (pg/mL)

13,598 ± 4046

19,171 ± 5689

15,309 ± 4172

CSF Aβ42/40

0.076 ± 0.01

0.032 ± 0.01

0.036 ± 0.006

CSF Tau (pg/mL)

198 ± 64.4

631 ± 214

558 ± 178

CSF pTau181 (pg/mL)

37.3 ± 12.1

101.4 ± 29.8

89.9 ± 18.4

Plasma NfL (pg/mL)

22.0 ± 12.4

38.1 ± 15.9

49.1 ± 28.4

  1. Values are shown as averages ± standard deviations or as numbers per group
  2. amyloid β, AD Alzheimer’s disease, ADD Alzheimer’s disease dementia, CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini Mental State Examination, NfL neurofilament light chain
  3. aAvailable in 22 cases
  4. bAvailable in 23 cases